

Project Revive - frequently asked questions

1) Who can participate in Project Revive?

Project Revive is open to all Marketing Authorisation holders (MAH) of Non-Marketed MHRA approved Marketing Authorisations (MA) covering products in the lists developed by MPSC, NHS England. The lists are available from Medicines UK. If companies in the supply chain, such as contract manufacturers, wish to be involved to support MAHs, please contact Medicines UK; Robert Russell-Pavier (robert.russellpavier@medicinesuk.com).

Medicines UK will circulate your company contact details to Medicines UK members, as well as other MAHs that have declared initial interest in Project Revive.

2) Who can I discuss specific products with to inform whether my company expresses formal interest in supplying a product on the Project Revive lists?

Please contact Mark Cartwright in NHS England's Medicines Procurement and Supply Chain team via markcartwright@nhs.net.

To register your initial informal interest in Project Revive, or to receive the list of in-scope products, please contact Mark Cartwright markcartwright@nhs.net.

3) Who can I have a discussion with about matching anticipating volumes with batch size quantities to avoid wastage and support cost-effective expressions of interest?

Please contact Mark Cartwright in NHS England's Medicines Procurement and Supply Chain team via markcartwright@nhs.net.

4) When by and how do we express formal interest in a product?

You will need to express formal interest in a product(s) by end of the day Monday 1 June 2026.

This is to be done by completing and returning a spreadsheet to markcartwright@nhs.net.

The spreadsheet is designed simply to fill in and is provided alongside this FAQ. Companies can also request an electronic copy of the spreadsheet from Jackson.Lynn@medicinesuk.com. By submitting a formal expression of interest in supplying a product, companies will be formally included in the project however note this does not replace any procurement stage nor commit the supplier to supplying the specified products.

5) What is the price negotiation process?

Prices will not be subject to negotiation. In line with the requirements under the Procurement Act 23 MPSC will undertake a compliant tendering process, where bidders will submit their prices against the list of identified products. Successful bidders will be awarded a place on the MPSC framework. Evaluation criteria for this process will be bespoke due to the nature of this tender.

MPSC will organise a tender for products where formal interest has been declared by one or more company. This may include instances where there is already one supplier supplying a product to the NHS through an MPSC framework agreement and one or more other companies declare formal interest in supplying the product.

6) What happens if only one company declares an interest in bidding.

The company would submit a bid and set out how much volume they can supply, which MPSC will review, respond to and confirm whether the desire is to add this to a tender process based on individual circumstances.

7) What happens when a company is already on a framework agreement contract, and another supplier express formal interest to supply the product?

Where formal interest has been declared by one or more company of a product, MPSC will directly engage with interested parties and decide if it is to be added to the agreed list of products that will be tendered.

For further information please contact Medicines UK in the first instance via jackson.lynn@medicinesuk.com or robert.russellpavier@medicinesuk.com.

Project Revive is aimed at the existing pre-circulated product list.

However, if the concept is successful, the aim is that the list will be updated and added to annually by MPSC.

16) Can companies who haven't got dormant licences be a part of this initiative?

The purpose of Project Revive is to maximise supply from existing inactive Marketing Authorisations. A future project may include new Marketing Authorisations (MA) for targeted products.

If you have a submitted but not approved MA application or are planning to submit a MA application, then normal procedures and timelines apply for both the UK national licensing route and International Recognition Procedure.

17) What is the governance oversight for Project Revive?

Project Revive as a concept was announced as an action to be delivered in the Government's Supply Resilience Strategy, published August 2025.

Project Revive was launched with the support and input of NHS England, the Department of Health and Social Care and MHRA. MHRA and NHSE senior representatives sit on the project board, alongside Medicines UK.

For further information please contact Medicines UK in the first instance via jackson.lynn@medicinesuk.com or robert.russellpavier@medicinesuk.com.

8) Are all participants guaranteed an award?

MPSC will review the expressions of formal interest and follow up direct supplier engagement, to create the agreed list of products that will be tendered. Awards will be subject to compliance with the criteria within the Procurement Specific Questionnaire and evaluation criteria within the tender. Due to the nature of this project the aim is that all participants will achieve an award. This includes where a company may already be supplying a product on the list through an MPSC framework agreement.

9) When are the awards made? When does supply need to begin?

This will be confirmed precisely but expectation is that awards will be made towards to the end of 2026. The hope is that products will re-enter the market in early 2027 (or before). The supply date will be agreed by MPSC and the newly contracted parties through Project Revive as further detail arises through supplier engagement.

10) How long will the contracts last for? What happens when these contracts end?

The contracts will typically last around 24 months in duration and the end date will likely vary as the aim is that they will move into the next framework agreement wave following the end of the 24 months supply period. After this, the product will be treated under the normal MPSC framework agreement terms and conditions.

11) Will the contracts contain non-supply penalties?

They will not apply in the terms and conditions where Project Revive is successful in creating additional contracted suppliers. The aim is to encourage new supply routes where this has previously proven difficult.

12) Will MPSC commit to the NHS ordering and paying for a minimum quantity of product?

MPSC procurement operates by providing indicative volumes to market participants and conducting tenders on behalf of NHS trusts, the results of which trusts are then strongly encouraged to follow through by purchasing from the successful regional or national framework contracted supplier.

No guarantees can be made by the NHS regarding minimum sales volumes and it should be assumed that risk will be held by the supplier/manufacturer.

13) If regulatory changes are or could be needed, what is the MHRA contact point for Project Revive?

Eligible Marketing Authorisation Holders can receive regulatory advice from the MHRA.

Please email scientific_advice@mhra.gov.uk with 'PROJECT REVIVE' in the subject header, the product name, and the product licence number.

This can be done prior to formal expression of interest or afterwards. It is expected that any regulatory changes will run in parallel to the procurement process.

14) Will there be visibility on the overall progress of Project Revive, as well as individual company formal expressions of interest?

The project team will ensure regular high-level updates are communicated to those who express an interest.

This will not be communicated publicly if products are later awarded a place on the framework, the details (excluding commercially confidential details) would be in the public domain, in line with the Procurement Act requirements.